tiếng anh giao tiếp tập 3
Báo cáo y học: "Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study" pdf
Ngày tải lên :
12/08/2014, 15:22
... 0.841 NS 0 .38 1 0. 030 Haptoglobin 0. 131 0.0 03 0.6 93 NS 0.276 0 .34 3 0.006 0.4 83 NS 0.975 NS 0.472 0.020 0.511 0.572 NS NS Interleukin-16 0.015 0.9 03 NS 0.628 NS 0 .30 4 0.015 0 .34 6 0.025 2. 239 0.028 ... ± 9.2 (4-48) 14.2 ± 9.6 (5- 43) 13. 5 ± 9.0 (4-51) Tender joint count 21 .3 ± 12 .3 (6-62) 21.4 ± 13. 1 (5-58) 23. 2 ± 16.8 (4- 63) 24.1 ± 13. 4 (6- 53) 22.5 ± 13. 7 (4- 63) FACIT-F (0-52) 26 ± 11 (4-50) ... (0 .3- 10.8) 2.16 ± 2.77 (0 .3- 11.7) 1.20 ± 1. 53 (0 .3- 7.0) 1 .38 ± 1.44 (0 .3- 6.2) 1.70 ± 2.18 (0 .30 -11.7) Swollen joint count 13. 0 ± 5.7 (5-26) 13. 9 ± 10.4 (5-51) 12.5 ± 9.2 (4-48) 14.2 ± 9.6 (5- 43) ...
- 11
- 329
- 0
Báo cáo y học: "Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study" pps
Ngày tải lên :
08/08/2014, 23:21
... 0.08 (0. 23) 0.04 (0.17) 0.05 (0.19) 0.07 (0.22) 84.4 46.2 43. 3 66.8 24.9 50.7 37 .2 69 .3 30 .3 57.1 34 .2 69.1 27.5 63. 4 30 .1 74.2 42.5 64.1 26.7 70.1 52.2 39 .0 49.8 61.2 38 .3 52.4 38 .5 61.5 38 .4 40.2 ... 0.5124 0 .33 43 0 .35 23 0 .30 77 < 0.0001 1.406 1 .34 0 1.156 0. 936 1.068 1.094 1.608 0.962 0 .32 9 1.070 1.647 1. 136 1.040 to 1.901 0.617 to 2.911 0. 838 to 1.5 93 0.6 73 to 1 .30 2 0.686 to 1.6 63 0.676 to ... antipsychotic treatment duration† 2, 039 63, 878 56, 138 36 ,857 7,1 83 10,7 43 2,956 18, 132 0.25 0.19 0.26 0 .30 0. 13 0.16 0. 13 0.16 0.18 0 .30 0.15 0.18 0. 03 0.04 0.24 0 .30 *Because of rounding, these percentages...
- 10
- 379
- 0
Báo cáo y học: "Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis" pot
Ngày tải lên :
09/08/2014, 08:23
... 1. 83 3.72 5.94 3. 29 3. 05 1.96 3. 28 1 .33 2.59 Depletion 0.80 5.50 7.72 7.20 n.d 5.40 n.d 6.97 2.45 5.21 Repopulation 1.79 n.d 16 .3 4.70 4.08 n.d 4.54 2.00 4.94 Recovery 3. 98 4.47 14.1 3. 03 3 .30 ... 1 .33 1 .31 1.90 2 .30 1.08 4.27 7.90 n.d 2.62 n.d 4.06 3. 12 3. 51 4.41 months post-treatment 5.88 6 .34 4.46 2. 83 1.59 Baseline 409 77.8 189 5.04 96.7 124 179 23. 7 39 .5 Depletion 412 54 .3 n.d 2. 53 ... S4 S5 S7 S11 S 13 S14 S16 S17 S19 S20 27/F 56/F 33 /F 50/F 33 /F 33 /F 19/F 35 /F 56/F 51/F Baseline 25 14 12 22 14 12 Depletion 11 13 10 n.d 16 11 12 n.d months post-treatment 11 13 n.d n.d Baseline...
- 10
- 485
- 0
Báo cáo y học: " Unintegrated HIV-1 provides an inducible and functional reservoir in untreated and highly active antiretroviral therapy-treated patients" potx
Ngày tải lên :
13/08/2014, 05:22
... 21 22 23 naive naive naive naive naive naive pti pti pti naive pti npti 3TC+ABC+NVP 3TC+ABC+NVP ABC+3TC+NFV ABC+3TC+NVP 3TC+EFV+TNV AZT+ABC+3TC+LVP/RTV 3TC+TNV+SQV/RTV 3TC+TNV+NVP TNV+ABC 3TC+ABC+LVP/RTV ... 3TC+ABC+LVP/RTV AZT+3TC+DDI Duration of virologic suppression (month) Plasma HIV-1 RNA level (copies/ml) CD4+ T cell count (cells/µl) 5, 634 21,580 1,246 72, 539 42, 536 2,156,097 184,7 13 1 63, 435 11,869
- 12
- 128
- 0
Báo cáo hóa học: " Epidermal growth factor receptor gene copy number in 101 advanced colorectal cancer patients treated with chemotherapy plus cetuximab" doc
Ngày tải lên :
18/06/2014, 16:20
... vs yes 1.84 (1.07 - 3. 15) 0. 03 2.20 (1. 03 4.70) 0.04 Number of Lines: II-III vs I 2.20 (1.25 - 3. 89) 0.01 4.60 (1.87 11 .31 ) 0.001 EGFR score: 0-1 vs 2 -3 2.27 (1 .35 - 3. 82) 0.002 1.99 (0.89 ... 100 Male 62 61 Female 39 39 Median age (years range) 63( 26-80) Gender Performance Status 79 78 20 20 >1 2 Colon 79 78 Rectum 22 22 Liver metastases 79 78 77 76 >1 24 24 43 42 1-2 40 40 >2 18 18 ... Chianesi 53, 00144 Rome, Italy, 2Department of Pathology, Regina Elena Institute, via E Chianesi 53, 00144 Rome, Italy, 3Department of Clinical Pathology, Regina Elena Institute, via E Chianesi 53, ...
- 8
- 472
- 0
Báo cáo y học: "Two-year Outcome of Turkish Patients Treated with Zotarolimus Versus Paclitaxel Eluting Stents in an Unselected Population with Coronary Artery Disease in the Real World: A Prospective Non-randomized Registry in Southern Turk
Ngày tải lên :
25/10/2012, 11:18
... (62.7) Paclitaxelb (n:101) 58 (10.2) P Valuec 36 (36 ) 64 ( 63) 55 (54) 69 (68) (7) (6) (3) 34 (34 ) 47 (47) 20 (20) 5 233 .8 (57.4) 150 .3 (48.4) 39 .4 (8 .3) 158.6 (101.2) 114.7 (46.4) 5 2 Abbreviations: ... 31 (4) mme Stent length, mme 26 (4) Lesion length, 21 (3) mme Type of lesion, No (%) A (3) Bı 52 (45) B2 12 (10) C 49 (42) Paclitaxelb (n:101) P Valuec 76 (75) (9) 16 (16) 67.4 (7 .3) 31 (5) 36 9 ... Paclitaxelb (n:116) (n:101) P Valuec (4 .3) (3. 4) (2.6) (4.9) (3. 9) (6.9) 0.6 0 .3 0.002 (1.7) (2.6) (1.7) 12 (10) (5.9) (5.9) (0.9) 18 (17.8) 0.049 0.02 0.7 0.0 03 Indicates patients who received zotarolimus-eluting...
- 6
- 550
- 0
Tài liệu Differences in 4-Year Health Outcomes for Elderly and Poor, Chronically III Patients Treated in HMO and Fee-for-Service Systems ppt
Ngày tải lên :
14/02/2014, 07:20
... -4.6 36 45.7 822 14 13 X2 =14.1 53 -1.9 -2.9 to -0.9 26 58 17 47.6 0.7 -1.1 to 2.5 17 60 23 15 48.8 1.2 0.4 to 2.0 15 64 21 489 44.4 -3. 6 -5.2 to -2.0 33 1746 45.2 -2.9 -3. 7 to -2.1 27 58 50.3T ... 47.9 (0.8) 1 .3 Poverty Prepaid (HMO) 489 295 43. 3 (0.9) -4.0 -6.2 to -1.8 32 Fee-for-service 194 45.1 (0.8) -3. 3 -5.7 to -0.9 36 46 Nonpoverty Prepaid (HMO) 1746 879 45 .3 (0.5) -2.2 -3. 6 to -0.8 ... -3. 9 to 3. 1 14 X 2=4 .3 71 14 -1.2 to 3. 8 17 57 26 18 18 13 57 47.9 (0.5) 1.4 0.2 to 2.6 11 Xz=2.59 70 12 =2 .34 62 49.5 (0.5) 1.0 -0.8 to 2.8 16 66 X2=24.21 Fa,1s1e=2.711 4y A* X2= 23. 0** Fa,3s3-4.2#...
- 9
- 621
- 0
Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India pot
Ngày tải lên :
06/03/2014, 04:20
... 51 (11.2) 32 10 (31 .2) 3. 6 (1.5–8.5) Ͻ0.01 4.8 (2.0–11.6) 4 03 49 (12.2) 100 13 ( 13. 0) 1.1 (0.5–2.2) 224 27 (12.1) 279 35 (12.5) 1.0 (0.6–1.8) 241 33 ( 13. 7) 248 27 (10.9) 1 .3 (0.7–2 .3) 3. 1 (1.6–6.0) ... (14.0) 33 7 39 (11.6) 1.2 (0.7–2 .3) P value aOR (95%CI) 0.1 0.2 0.7 0.5 260 19 (7 .3) 226 41 (18.1) 2.8 (1.5–5.2) Ͻ0.001 32 6 30 (9.2) 160 30 (18.8) 2 .3 (1 .3 4.1) Ͻ0.01 32 9 28 (8.5) 162 32 (19.8) ... months 13 18 months Total relapse (6–18 months) Migrated Absence (a) 16 30 33 32 Relapse Sputum collection (b) COV % b/(aϩb) n (c) % (c/b) 480 4 23 405 5 03* 94 93 93 — 48 62 10.0 2.1 1.2 12 .3 Note:...
- 6
- 532
- 0
Báo cáo hóa học: " Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients" pot
Ngày tải lên :
18/06/2014, 16:20
... Male [ 63. 6] 10 [71.4] female [36 .4] [28.6] 49 55 Gender Age (median) paraprotein subtype G 0.99 [27 .3] [64 .3] [9.1] [21.4] D [18.2] [0] LC [45.5] [14 .3] I & II [ 63. 6] [50] III [36 .4] [50] [27 .3] ... Paraprotein subtype ISS 0 .38 2 0.026 0 .39 3 0.645 VAD chemosensitivity 0.887 0.974 VGPR after induction 0.722 0.406 VGPR after auto-HSCT 0.181 0 .35 7 Oligoclonal reconstitution 0.170 0. 039 DAPK methylation ... [28.6] [54.5] 10 [71.4] [27 .3] [7.1] ISS stage ≥VGPR after induction No Yes 0.69 0.227 ≥VGPR after ABMT 0. 03 Oligoclonal reconstitution Yes no DAPK methylation methylated 0. 434 0.216 unmethylated Figure...
- 7
- 489
- 0
Báo cáo hóa học: "DNA polymeraseh protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy" pot
Ngày tải lên :
18/06/2014, 16:20
... Male 49 61 .3 Female 31 38 .7 36 42 45.0 52.5 2 2.5 Cardia 21 26 .3 Body 18 22.5 Antrum/pylorus 41 51.2 Liver Lung 26 21 32 .5 26 .3 Peritoneum 19 23. 8 Others 14 17.4 G1 2.5 G2 26 32 .5 G3 52 65.0 treatment ... 0.889 0 .30 8 0.929 0.525 2% 0.500 0.889 0 .34 0 0.940 0.588 3% 0.645 0.889 0.421 0.952 0.700 4% 0.8 23 0.889 0.5 93 0.962 0. 838 5% 0.887 0.889 0.696 0.965 0.888 6% 0.887 0.778 0.667 0. 932 0.8 63 Treatment ... photoproducts Mol Cell Biol 19 93, 13: 4276- 83 Page of 33 Lehmann AR: Replication of damaged DNA in mammalian cells: New solutions to an old problem Mutat Res 2002, 509: 23- 34 doi:10.1186/1479-5876-8-126...
- 9
- 610
- 0
báo cáo hóa học:" Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients" pdf
Ngày tải lên :
20/06/2014, 08:20
... ( 63% ) 141 (74%) 135 (57%) years 172 (39 %) 83 ( 43% ) 89 (36 %) years 116 (27%) 53 (28%) 63 (26%) years 76 (17%) 31 (16%) 45 (18%) years years 1 43 (56%) 83 (32 %) 70 (56%) 40 (32 %) 73 (55%) 43 (32 %) ... 15 (3% ) (4%) (2%) 14 (6%) 11 (4%) undifferentiated 33 (8%) 20 (11%) 13 (5%) other types 31 (7%) 17 (9%) 14 (6%) Histological grade G2 54 ( 13% ) 24 (12%) 30 (12%) G3 2 63 (60%) 110 (58%) 1 53 ( 63% ) ... 1. 23 [1.22,4.07] 0.009 2. 23 [1.06,4.67] 0. 033 > cm 3. 41 [1.88,6.18] 0.000 2.99 [1.45,6.17] 0.0 03 Grade Grade 1.0 2.92 [1.45,5.86] 0.0 03 1.0 3. 53 [1.45,8.61] 0.005 Grade 2.98 [1.44,6.15] 0.003...
- 9
- 407
- 0
báo cáo hóa học:" Substitutions in the Reverse Transcriptase and Protease Genes of HIV-1 Subtype B in Untreated Individuals and Patients Treated With Antiretroviral Drugs" potx
Ngày tải lên :
20/06/2014, 08:20
... L74V (3. 9) E44A/D (5.8) T215Y (33 .3) V75I (0) L210W (25.4) K219E (11.7) E44D (0) K219Q (7.8) Q151M (3. 9) T215F (11.7) T215Y (33 .3) RT (NNRTI) (n = 12) V108I (25) Y181C (33 .3) G190S (0) P 236 L (0) ... (8.8) G73S (11.7) V77I (8.8) V82T (5.8) RT (NRTI) (n = 51) D67N (19.6) K65R (0) A62V (0) V75I (5.9) K70R (31 .3) T215F (11.7) V118I (25) M184V (76.4) G 333 A (NA) F77L (0) M41L (21.5) Q151M (3. 9) L74V ... Another high-prevalence mutation was T215Y (33 .3% of patients), which is a result of both CA and AT transversions Among NNRTI-treated patients, 33 .3% harbored the Y181C mutation, which results...
- 6
- 286
- 0
báo cáo hóa học: " F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin)" pdf
Ngày tải lên :
21/06/2014, 02:20
... [91%] 674 [122 .3% ] 53 [59.6%] 607 [110.2%] 50 [56.2%] 2 73 [107.5%] 406 [1 03. 3%] 38 .2 (26.5-46.9) [51.2%] 30 .7 (21.1-59.4) [111.6%] 18.8 (9.8-24.8) [84 .3% ] 298 [117 .3% ] 290 [ 73. 8%] C3, L1, L5, L ... [90.4%] 33 2 [ 43. 6%] 3. 7 (2.9-4.8) [24.7%] 35 0 [68.9%] 225 [29.6%] 74.6 (54.7-98) 78 129 66.7 (51 .3- 76.7) [89.4%] 92 [117.9%] 85 [65.9%] 57 [ 73. 1%] 70 [54 .3% ] 25 .3 (20.6-29.5) [92%] 20 .3 (11-25) ... metastases) ilium, L femur 46.4 (33 .1-75 .3) 37 0 118 31 .3 (26.5-40.5) [67.5%] 210 [56.8%] 47 [39 .8%] 22.1 (16.7-28.2) [47.6%] 207 [55.9%] 53 [44.9%] B (superscan) 15.0 ( 13. 2-17.2) 508 761 16.0 (11.9-21.1)...
- 6
- 286
- 0
Báo cáo y học: "Primary Care Outcomes in Patients Treated by Nurse Practitioners or Physicians" docx
Ngày tải lên :
07/08/2014, 00:20
... Role-physical 33 .55 (42.88) 32 .28 ( 43. 53) Bodily pain 38 .10 (29.72) 39 .25 (29 .36 ) t = −0. 231 P = 82 t = 0 .30 6 P = 76 General health 38 .06 ( 23. 02) 37 .08 ( 23. 48) t = −0 .33 3 P = 74 Vitality 43. 06 (25.21) ... 60 .30 64.26 t = 4. 631 64.94 62.90 t = −1.126 64.21 63. 78 t = 0 .39 4 P = 26 P = 77 36 .06 53. 31 t = 10.519 53. 74 52.62 t = −0 .37 5 52.92 53. 38 t = −0.192 P = 71 P = 85 42.74 53. 01 t = 9. 133 53. 66 ... 130 9) Primary care visits mo After Change, (N = 130 9) z Score† 22.2 18.0 16.1 18.0 16 .3 14.5 12.8 9.8 9.6 6.1 5 .3 9 .3 9.4 89.1 5.6 62 .3 14.2 61.8 63. 1 13. 3 15.7 2 .3 9 .3 10.8 7.1 3. 1 14.2 14.3...
- 10
- 411
- 0
Báo cáo y học: "Brain choline concentrations may not be altered in euthymic bipolar disorder patients chronically treated with either lithium or sodium valproate" pps
Ngày tải lên :
08/08/2014, 20:23
... Sex 50 45 43 39 37 36 35 32 32 30 28 37 .00 M M F M F F M F M F M 3. 51 2.19 3. 01 2.11 2.47 1.91 1.76 1.88 1.94 1.82 1.72 2.21 2.95 3. 03 2 .31 2.72 2 .34 1.76 2 .36 1.51 2.14 2.52 2. 23 2 .35 6.67 10.1 ... 9.79 8.01 7. 23 8.81 0 .30 0 .32 0.24 0.25 0 .33 0.22 0 .33 0.24 0 .31 0.28 0.21 0 .33 0.24 0. 23 0 .34 0.27 0.19 0 .37 0 .31 0.28 Valproate Treated Patients Mean 58 50 49 48 36 35 35 34 34 42.11 These findings, ... 2.61 2. 03 2.44 2.60 2.07 2.78 1.76 2. 43 2 .38 2.1 3. 42 1.79 1.88 2. 53 2.77 1.89 2. 93 2.27 2.40 9.16 8.17 8.56 9. 93 7.84 9.26 8 .35 7.26 7.75 8.48 10. 13 10. 53 7.48 8.19 7.51 10 .39 9.79 8.01 7. 23 8.81...
- 7
- 430
- 0
Báo cáo y học: "Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept" pot
Ngày tải lên :
09/08/2014, 01:21
... 10/7 13. 7 (2.5–41.0) 36 (1–85) 11 .3 (5.5–19.2) 12.2 (8.1–29.7) DAS28 at baselinea 5 .3 (2.4–8.1) 5.9 (3. 7–7.5) HAQ at baselinea 1.4 (0.4–2.8) 1.6 (0 .3 2.8) Monotherapy/combination therapy 5/27 3/ 14 ... No 32 Age (years)a 56.7 ( 23. 5–80.9) Female/male Duration of disease 25/7 (years)a Serum CRP at baseline (mg/l)a Serum COMP at baseline (u/l)a 12.9 (3. 0–55.5) 20 (1–84) Etanercept 17 55 .3 ( 23. 2–70.4) ... Rheum 1988, 31 :31 5 -32 4 DiCesare P, Hauser N, Lehman D, Pasumarti S, Paulsson M: Cartilage oligomeric matrix protein (COMP) is an abundant component of tendon FEBS Lett 1994, 35 4: 237 -240 Smith...
- 5
- 486
- 0
Báo cáo y học: "Circulating tumour necrosis factor-α bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical respone" pot
Ngày tải lên :
09/08/2014, 06:22
... ± 2.70 0. 43 Tender joint count (0–28) 9.21 ± 5.78 8 .35 ± 6.07 0.80 DAS28 score 5 .33 ± 1.12 5 .31 ± 1.19 0.76 ESR (mm/hour) 37 .59 ± 23. 18 37 .45 ± 23. 71 0.91 CRP (mg/l) 26. 93 ± 24.87 31 .30 ± 27.24 ... 0.97) Similar results were observed with p55 (2 534 ± 1074 pg/ml versus 2 436 ± 9 53 pg/ml; P = 0.57) and p75 (30 54.8 ± 6 73. 8 pg/ml versus 233 2.2 ± 921 .3 pg/ml; P = 0.84) soluble receptors in good ... obtained at baseline from 20 RA patients The mean TNF-α level was 144.87 ± 130 .36 pg/ml in good responders and 1 53. 75 ± 132 . 93 Available online http://arthritis-research.com/content/7/1/R149 Figure...
- 7
- 453
- 0
Báo cáo y học: "Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs" ppsx
Ngày tải lên :
09/08/2014, 07:20
... http://arthritis-research.com/content/8/2/R42 25 26 27 28 29 30 31 32 33 34 ing concomitant methotrexate: a randomised phase III trial ATTRACT Study Group Lancet 1999, 35 4:1 932 -1 939 Reimold AM: New indications for treatment ... ± sd) 47.24 ± 14. 63 Age at diagnosis (mean ± sd) 33 .88 ± 14. 53 Disease duration (mean ± sd) 13. 16 ± 7. 83 Clinical manifestations, n (%) Malar rash 102 ( 53. 1) Discoid lesions 38 (19.8) Subacute ... 1.64 (0.52–5.24) 0.400 1.77 (0.47–6. 63) 0 .39 7 High/High 10 (2.9) (2.5) 13 (8.6) 0.48 (0.06–4.02) 0.499 0. 43 (0.04–4.21) 0.472 0 .38 6 0.59 (0.20–1.78) 0 .35 4 -30 8 TNFα Referent 0.024 2.67 (1.20–5.97)...
- 9
- 347
- 0
Báo cáo khoa học: "Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients" pot
Ngày tải lên :
09/08/2014, 08:23
... (9) 0. 03 Anti diarrhea drug used No 21(68) 29(91) Yes 10 (32 ) 3( 9)
- 6
- 261
- 0